Question 1

What amounts of larazotide did the trials use?

Accepted Answer

Four sets of figures cover the coeliac trials behind this page, and each was selected to examine a range rather than to identify a single amount. The 2007 proof-of-concept study gave 12 mg doses to people with coeliac disease who were then challenged with gluten. The 2012 dose-ranging trial randomised 86 patients to larazotide at 0.25, 1, 4 or 8 mg, or placebo, three times a day. The 2013 trial narrowed that span, randomising patients to 1, 4 or 8 mg three times daily or placebo. The 2015 trial then moved lower again and assessed 0.5, 1 or 2 mg three times daily in adults with persistent symptoms. Read chronologically, the trials drifted downward, from a 12 mg single administration to a 0.5 mg arm, as successive investigators found the smaller amounts performing at least as effectively as the larger ones. Every one of these figures is an individual oral amount, not a daily total.

Question 2

How often was larazotide taken in the trials?

Accepted Answer

Three times daily in every coeliac trial that specifies a schedule, and four times daily in the paediatric work. The coeliac schedule is consistent with the reasoning behind larazotide: gluten arrives with meals, so the compound presumably needs to be present in the intestine throughout the day. The trial summaries behind this page do not specify when each administration occurred relative to food, so that detail cannot be reported. In the children with the post-COVID inflammatory syndrome, a 2022 case series gave larazotide orally four times daily for 21 days. The later phase 2a trial in 12 children used the same four-times-daily pattern. Neither of those schedules was organised around meals and gluten. They were intended to maintain the intestinal barrier during an acute hospital illness, which represents a different purpose and a different patient population from the coeliac trials.

Question 3

Who received those amounts?

Accepted Answer

Mostly adults with established coeliac disease, and a handful of children in hospital. The adult trials enrolled people whose disease was managed through diet, so the amounts were tested against a background of strict gluten avoidance, sometimes with gluten added back on purpose. The registry also lists a completed phase 2 study of larazotide in people with active coeliac disease, whose detailed results are not among the sources behind this page. The only weight-based figure comes from the children. Patients were treated with open label larazotide at 10 micrograms per kilogram, with a maximum of 500 micrograms per dose, in the 2022 case series. Open label means everyone knew what was being given. That figure was set by doctors for sick children of very different sizes, from 3 to 17 years old, and it cannot be compared directly with the fixed milligram amounts used in adults, nor turned into an adult figure.

Question 4

How was larazotide given in the studies?

Accepted Answer

Orally in every human study behind this page, and by a considerably wider variety of routes in animals. In the clinical trials participants swallowed it. In rats, a 2024 pancreatitis experiment gave a preventive 0.01 mg per millilitre solution of larazotide by mouth for 7 days before the illness was induced. In mice with acute lung injury, a 2013 study gave it directly into the airway or into a vein instead. A pig study used the oral route in a manner closer to the human trials, giving 1 mg in total to pigs that had fasted overnight. Each of those choices served a particular experimental purpose. An oral solution, an administration into the airway and a single oral amount in a pig cannot be compared against one another, and none of them can be scaled into a figure for a person. We report them only to demonstrate how differently the same molecule has been delivered.

Question 5

How much of a swallowed dose reaches the small intestine?

Accepted Answer

In pigs, enough to measure, and it lasted for a few hours. The 2021 pig study tracked how much larazotide was present in fluid taken from the gut after it had been given by mouth. Peak concentrations of 0.32 to 1.76 micromolar occurred at 1 hour in the duodenum and upper jejunum, the first stretches of small intestine. Smaller amounts, from 0.02 to 0.47 micromolar, were still present in the lower duodenum between 2 and 4 hours after dosing. Micromolar is a measure of how many molecules occupy a given volume of fluid, not a weight. Those readings may help explain the three-times-daily pattern in the trials, since the concentration at the target appears to decline within a few hours. They describe one oral dose of one formulation in pigs that had fasted overnight. They cannot indicate how much of a different material, taken in a different way, would reach a human intestine.

Question 6

Did more larazotide work better?

Accepted Answer

No, and this is the most consistent pattern in the entire dosing record. In the 2012 trial, larazotide appeared to limit gluten-driven worsening of symptoms at some lower doses but not at the higher dose. In the 2013 trial, the 1 mg amount limited gluten-induced symptoms on the standard rating scale, with a P value of 0.002 against placebo. The 2015 trial made the pattern hardest to miss. Its authors concluded that 0.5 mg reduced signs and symptoms in patients better than a gluten-free diet alone, while describing the results overall as mixed. So three trials, with different designs, each found the smallest or a relatively small amount producing the effect. A response that diminishes as the amount increases is unusual, and it is precisely why a figure from one arm of one trial cannot be treated as a target. It also means that selecting a larger amount in anticipation of a larger effect has no support in these trials.

Question 7

Why might a smaller amount of larazotide do better?

Accepted Answer

A 2021 experiment on pig intestine offers one explanation, though only in tissue rather than in people. Researchers damaged strips of pig gut by cutting off the blood supply, then let them recover in the laboratory with larazotide present. They concluded that larazotide stimulated repair at the tight junctions, at an optimal concentration of 1 micromolar, while lower and higher concentrations did less. The reason, they argued, was fragments. An enzyme on the gut surface chops larazotide into pieces, and one piece blocked the repair effect, so more parent molecule meant more of the blocking fragment. The authors suggested the problem could be avoided by chemically modifying the molecule or by microdosing, meaning very small amounts. That is a hypothesis from tissue in a laboratory chamber. It fits the trial pattern neatly, but it has not been tested in a trial, and fitting a pattern is not the same as explaining it.

Question 8

How much gluten did the trials give alongside larazotide?

Accepted Answer

Between 2.4 and 2.7 grams a day, in the trials that tested it against gluten, and that shapes how every amount above should be read. The 2022 meta-analysis records that three of its trials ran a gluten challenge at an intake of 2.4 to 2.7 grams of gluten a day, while two reported results in patients on a gluten-free diet. Those are not the same test, and an amount that helped in one setting need not help in the other. A gluten challenge is a deliberate exposure. It is used because it provokes symptoms predictably, so that a difference between the groups becomes measurable within a few weeks. It is an experimental tool rather than a copy of the accidental gluten that turns up in daily life. So the trial amounts of larazotide were evaluated against a fixed and known gluten load, which is not how gluten usually appears in an ordinary diet. An amount that blunted symptoms against a standard daily challenge may behave quite differently against small traces eaten at irregular times.

Question 9

How long did the larazotide courses last?

Accepted Answer

From a single administration day to 12 weeks, with nothing longer in the trials behind this page. The earliest study examined single doses given in hospital. The 2012 trial continued for 14 days, the 2013 trial for six weeks, and the 2015 trial for 12 weeks of active treatment. Outside coeliac disease, the paediatric courses lasted three weeks. The duration of each course was determined by the question the trial was investigating. A two-week course can reveal whether symptoms increase during a gluten challenge, whereas a 12-week course is necessary to evaluate persistent symptoms despite dietary management. None of these durations was designed to establish how long anyone might continue larazotide, and none of the trials examined outcomes after many months. The registry lists a second completed phase 2 efficacy study, whose duration does not appear among the sources behind this page.

Question 10

Is there a cycle or a break in the published work?

Accepted Answer

Not in the sense of alternating periods on and off, which no trial behind this page examined. What the trials did incorporate were placebo periods at either end. In the 2013 trial, patients went through a gluten-free run-in period before being randomised, so everyone started from a stable baseline. The 2015 trial wrapped its 12 weeks of treatment in placebo weeks before and after, and participants maintained their current gluten-free diet throughout. Those placebo windows are measurement instruments. A run-in establishes how symptoms behave without any active compound, and a run-out would reveal what happens after discontinuation. A measurement window and a rest period within a cycle are different things, and none of the trials compared continuous administration with intermittent administration. Any alternating schedule described for larazotide outside these trials has no foundation in the research behind this page.

Question 11

Is there an approved dose of larazotide?

Accepted Answer

No. An approved dose comes with an approval, and larazotide has none. A 2021 pig study opens by noting that there is no FDA-approved therapy for coeliac disease, aside from avoiding dietary gluten. So there is no label, no prescribing information and no officially recommended amount to report, for coeliac disease or anything else. That leaves only the trial figures, and each one belongs to a particular design: a particular formulation, a particular patient group, a particular gluten exposure and a particular length of course. Taken out of that setting, a number such as 0.5 mg three times daily describes one arm of one trial. It does not describe what larazotide would do for someone else, or what a different material sold under the same name contains. That is the reason this page reports amounts and declines to recommend one.

Question 12

What amounts appear in the animal and laboratory work?

Accepted Answer

A scatter of units that do not translate into one another, let alone into a person. In mice with lung injury, larazotide reduced the injury in a dose-dependent manner, meaning larger amounts had larger effects within the range tested. That is the opposite of the human trial pattern, which is itself a warning against borrowing figures across species and settings. In mice that develop colitis spontaneously, a 2009 study compared untreated animals with a high-dose group and reported a marked reduction in small intestinal permeability. In cultured human intestinal cells, larazotide blocked the passage of a gluten fragment across a cell layer, at concentrations set in the dish rather than doses. None of these studies was designed to find a dose for people, and the conversion methods that scale animal amounts to humans have not been validated for larazotide. We do not perform them, and the figures above are reported only as what each experiment used.

Larazotide protocols in the published literature